Abstract An absolute erythrocytosis is present when the red cell mass is greater than 125 % of the predicted value for sex and body mass. It can have a primary or secondary and congenital or acquired cause. New causes particularly congenital continue to be discovered and investigated. Investigation for the cause starts with repeat and confirmation of the raised hemoglobin and measurement of an erythropoietin level to indicate whether to pursue primary or secondary causes and then further investigations as appropriate. Management options include low dose aspirin and venesection. Specific management advice is available for certain specific clinical situations.
Introduction
An erythrocytosis is suspected when the hemoglobin (Hb) and/or hematocrit (Hct) is above the normal range for the subjects age and sex. However, by definition, a true erythrocytosis is present when the red cell mass is greater than 125 % of predicted for age and sex [1] . This defined true or absolute erythrocytosis is distinguished from an apparent erythrocytosis where the Hct is raised but the red cell mass is within the reference range and a relative erythrocytosis where the Hct is raised, the red cell mass is within the reference range and the plasma volume is reduced.
It cannot be assumed that there is a direct correlation between Hb and Hct measurement and red cell mass. This was well demonstrated by a study of Johannson et al. [2] where males and females had red cell masses carried out. In only 35 % of male patients with an Hb greater than 185 g/l had an absolute erythrocytosis, and in females, only 65 % with Hb above 165 g/l had absolute erythrocytosis. Conversely, these levels of Hb suggest a misdiagnosis of absolute erythrocytosis in 14 % of males and 35 % of female patients. However, it can be assumed if the Hct is greater than 0.60 in a male and 0.56 in a female then the red cell mass will definitely be elevated.
There are currently several controversial issues with the definition of an erythrocytosis. The first issue is that it is becoming increasingly difficult in most of the world to get a red cell mass study carried out in many counties for a variety of reasons including difficulties with the supply of radioisotope. This means that the confirmatory test for an equivocal Hb or Hct cannot be undertaken so that one is left in doubt if there is an actual absolute erythrocytosis. The second issue is that the World Health Organisation (WHO) has produced new criteria for the diagnosis of polycythaemia vera (PV). In these criteria, they state that an Hb above 165 g/l in a man or 160 g/l in a woman or an Hct above 49 % in a male or greater than 48 % in a woman plus the presence of a bone marrow biopsy with hypercellularity and panmyelosis and a JAK2 mutation makes a diagnosis of PV [3••] . These Hb and Hct values in males and the Hb value in females which fall within the normal range will raise the question of an erythrocytosis when there is a basically normal level of Hb and in most places a red cell mass cannot be performed to confirm or refute this. Obviously, the other criteria are required in addition to fulfill the diagnostic This article is part of the Topical Collection on Myeloproliferative Disorders criteria but the Hb and Hct levels of this order to not help in deciding who might be considered for the disorder.
Classification
Once an erythrocytosis is detected then, the next issue is establishing the cause. Causes can be divided into primary and secondary. An erythrocytosis is classified as primary where there is an intrinsic defect in the erythroid compartment of the bone marrow or secondary where erythropoietin (EPO) or something else is driving the bone marrow to produce more red cells. It can also be divided into congenital where the individual is presumed to be born with the defect and acquired where the cause occurs later in life. A full list of causes of erythrocytosis is detailed in Table 1 .
Congenital-Recent Findings
Gene mutations leading to erythrocytosis can be primary where there are mutations of the Erythropoietin receptor (EPOR) or secondary where causes include defects in the oxygen sensing pathway, high oxygen affinity hemoglobins, methemoglobinemia, and other congenital defects which lead to elevated EPO levels. Bento et al. attempted to provide a comprehensive list of all described mutations [4] from all information available including databases. However, clinicians continue to investigate and describe lesions in their patients. A mutation in exon 8 of the EPOR gene 6002delG has recently been reported in a young man with erythrocytosis. This nonsense mutation results in a stop codon and therefore a truncated EPOR protein [5] . This is of course the same size of truncation as was reported originally in the EPOR gene over 20 years ago [6] . In another series of patients with erythrocytosis who were reinvestigated two mutations in EPOR were identified. One was the previously described missense mutation (c.1310G>A, p.ARG437His). In another patient, a new nonsense mutation which leads to a stop codon was seen (c.1362c>G, p.Tyr454*). The EPOR protein is then truncated by 55 residues which is the shortest truncation which has been reported so far [7] .
In the genes in the oxygen sensing pathway, a homozygous VHL mutation (D126N) has recently been described in an infant with erythrocytosis. This child of Bangladeshi origin whose parents were first cousins had an extremely elevated EPO level. He developed pulmonary hypertension at the age of 16 months and died with viral respiratory infections and worsening pulmonary hypertension at the age of 2 years [8•] .
PHD2 mutations have been reported in association with paragangliomas and erythrocytosis [9] . Recently, a germ-line PHD2 mutation (c.682G>T, A228S) was seen in one patient with erythrocytosis and pheochromocytoma/paraganglioma. Another patient with the same clinical presentation was found to have a germ-line PHD1 mutation) c.188T>A, S61R) which is the first time PHD1 has been described causing this type of clinical picture [10••] .
Erythrocytosis associated with somatic gain-off u n c t i o n m u t a t i o n s i n H I F 2 A i n a s s o c i a t i o n paraganglioma [11] . These somatic gain-of-function mutations in HIF2A continue to be reported in association with paragangliomas, pheochromocytomas, and somatostatinoma associated with erythrocytosis (the so called Pacak-Zhuang syndrome). A new one of these w a s d e s c r i b e d r e c e n t l y i n a 1 5 -y e a r-o l d m a l e (c.1589C>A, Ala530Glu). This mutation was not present in germline DNA from leucocytes. EPO levels remained elevated even after the removal of tumor and it is speculated that paraganglioma was still present in other neural crest cells [12] . Clinicians need to be aware of the associations between mutations in the genes in the oxygen sensing pathway and neuroendocrine tumors and further investigation may be warranted.
Many of these gene mutations have been discovered by sequencing of individual genes where a lesion is suspected. However, technology is advancing. Whole genome sequencing is now being applied to patients in whom the cause of erythrocytosis has not been discovered and this may pick up lesions that have otherwise been overlooked. In such a study identified a novel missense mutation in the Bisphosphoglycerate mutase (BPGM) gene resulting in a G269A substitution. This was in a patient who had been followed up for some years with erythrocytosis [13] . It is likely in the future that technology such as targeted next generation sequencing will be used to investigate these patients.
Acquired
A primary acquired erythrocytosis is due to PV which is the commonest suspected diagnosis in most individuals referred to hematology with a raised Hb or Hct. Testing for the presence of a JAK2 clone plus possibly a bone marrow examination can confirm this diagnosis.
As can be seen from Table 1 , there are a myriad of factors which can cause or contribute to the development of a secondary acquired erythrocytosis. Issues which may be worth considering are smokers where measurement of CarboxyHb is a simple test to undertake and demonstrate recent cigarette consumption even in those who deny this. Another factor is the consumption of androgens and other drugs which stimulate the erythropoietic pathway. This is an activity which patients may not admit to and may be becoming more common with various gender assignment issues becoming prominent [14] .
Idiopathic Erythrocytosis
All investigators in the area see patients in whom no cause for the erythrocytosis can be identified. This group, referred to as idiopathic erythrocytosis, has decreased over time as more causes are identified but there remain many patients who fall into this category. In one large series, no simple criteria to distinguish these patients from other with familial erythrocytosis or PV were identified [15] .
Investigation
The sequence of investigation of an erythrocytosis is described in Fig. 1 . The investigation of an erythrocytosis must begin the confirmation of the raised Hb/Hct with a repeat of the full blood count after a reasonable time interval as a single elevated result is not sufficient evidence of erythrocytosis. Any patient investigation must start with a careful and thorough history and examination with cognisance of the causes of erythrocytosis. In this process, possible contributory lifestyle factors should be thoroughly investigated. An erythropoietin assay to measure the EPO level is a useful test to carry out early in the diagnostic process. The result of this test will indicate whether it is a primary erythrocytosis (where the EPO level is below the normal range) or a secondary erythrocytosis (where the EPO level is inappropriately normal or elevated). This distinction can then guide which further investigations should be carried out.
There are a number of other routine investigations which should be carried out at an initial stage listed in Table 2 . Further investigations many of which are more invasive are listed as stage 2 investigations and directed by the initial enquiries and results of stage 1 investigations. This includes Fig. 1 Diagram of pathway for investigation of an erythrocytosis consideration of a bone marrow biopsy. The WHO require a bone marrow biopsy for the diagnosis of PV [16] but others feel that the demonstration of a raised HB/Hct, and the presence of an acquired JAK2 clone is sufficient to make the diagnosis [17] ; however, this is certainly a test which should be considered as part of the diagnostic process.
The red cell mass measurement is a very useful confirmatory test for an absolute erythrocytosis in cases where the level of Hb or Hct is equivocal, and there are no other obvious confirmatory results such as the presence of JAK2 clone in possible PV. Unfortunately, this is a test which is becoming more difficult to obtain in many places. If the Hct is above 0.60 in a male and 0.56 in a female, then it can be assumed that at these levels the red cell mass is definitely above 125 % of predicted.
Management
In order to manage an erythrocytosis, one needs to consider if there are complications and if these lead to decreased survival. With an erythrocytosis, the viscosity is increased and the main issue is does this lead to increased thromboembolic events and would reduction of the thromboembolic tendency and/ or the viscosity reduce the complication rate and improve survival. There is a little evidence to guide the management of erythrocytosis particularly when it has a rare cause and support any management strategies which reduce viscosity.
There are however a couple of measures which could be employed. The first is low dose aspirin in order to interfere with platelet function and therefore ameliorate the thromboembolic tendency. This strategy was employed in the European Collaboration on Low Dose Aspirin (ECLAP) study in PV where those without clear indication were randomised between low dose aspirin and placebo. Those randomised to low dose aspirin had a reduced risk of both the combined end points which included nonfatal myocardial infarction, nonfatal stroke or death from cardiovascular causes and pulmonary embolism and major venous thrombosis [18] . By extrapolation therefore low dose aspirin may be of benefit in reducing the risk of thromboembolic events in other forms of erythrocytosis.
Venesection will reduce the Hct and therefore the viscosity. In a randomised trial in PV, comparing venesection to maintain the Hct below 0.50 or 0.45, the lower target Hct was associated with a significantly lower risk of cardiovascular death and major thrombosis [19••] . Again, it is extrapolated that a similar measure may be of benefit in other forms of erythrocytosis. The evidence for this is not available and the particular issue is that of a target Hct. In those with a very high Hct is may be impossible to achieve an Hct anywhere near 0.45, and this may not help the patient. In particular, in some of the congenital conditions physiological, studies have shown that the defect leads to abnormal physiological responses with abnormal pulmonary function and regulation of organ systems on which cellular oxygen delivery depends [20] . Thus, reducing the Hct too much may not be of any benefit to patients with oxygen sensing pathway defects.
Congenital Erythrocytosis
The largest group of patients with congenital erythrocytosis is those homozygous for the Chuvash mutation in Chuvashia and some retrospective studies have been done on this group and their outcomes and management. In this group, a comparison was made with controls and the patients with Chuvash polycythaemia who were found to have a reduced life expectancy due to an increased incidence of thromboembolic events. However, treatment with aspirin or the level of the Hct was not related to the events [21] .
In other congenital erythrocytosis due to mutations in the oxygen sensing pathway, there are reports of major thromboembolic events occurring at a young age [22] . Pulmonary hypertension is also emerging as a complication in some cases [23] . With note of these clinical complications, low dose aspirin and venesection to an achievable target in considered in congenital erythrocytosis.
It has recently been shown that the VHL protein binds to the suppressor of cytokine signaling (SOCS1) and then after binding to E3 ligase, targets JAK2 for ubiquitin mediated destruction. The Chuvash VHL mutants were shown to have altered affinity for SOCS1 and do not degrade JAK2 and in mice, a JAK2 inhibitor reversed the disease phenotype [24•] . This raises the possibility that inhibitors of the JAK pathway available for therapeutic use may be of benefit in the treatment Chuvash polycythemia to block the JAK/STAT pathway and thus the development of erythrocytosis. Initial reports in patients suggest that this strategy may be of benefit [25] .
High Oxygen affinity Hemoglobins
Based on the available scare evidence, there is also some advice for the management of high oxygen affinity Hb. The Chest X Ray Globin gene sequencing Red cell mass presence of symptoms, for instance dizziness, dyspnea, or angina, for which the raised Hct is considered a contributory factor, is a possible indication for venesection. One or more previous thrombotic episodes would also be an indication for venesection. Asymptomatic individuals with an high oxygen affinity Hb in whom a family member with the same high affinity Hb, a similar Hb concentration and comparable risk factors, has developed a thrombotic problem should also be considered for venesection.
It is not possible or reasonable to reduce the Hct with venesection to achieve a Hct of less than 0.45 or approaching the normal range. The target for venesection should be to maintain the Hct less than 0.60. However, when there is thrombosis or symptoms compatible with hyperviscosity at an Hct less than 0.60 then a target of 0.52 may be adopted. In an individual with a high oxygen affinity Hb with an Hct above 0.60 who requires major surgery, a partial exchange transfusion should be considered [26] .
Management: Acquired Secondary Conditions Congenital Cyanotic Heart Disease
In congenital cyanotic heart disease, a compensatory erythrocytosis develops which aids oxygen delivery to the tissues. However, the Hb can be very elevated and these patients present a complex management problem and should be managed primarily by a congenital heart disease unit with specific specialist knowledge. However, isovolumic venesection should be carried out when the patient has symptoms of viscosity. No general target Hct can be suggested but treatment should be individualised for patients. It is of note that excessive venesection may produce iron deficiency which may compromise oxygen delivery to tissues and can raise the viscosity for a given Hb [27] . Iron therapy should be used judiciously as it may provoke a rapid rise in Hct.
Hypoxic Pulmonary Disease
Pulmonary disease is common and many of these patients may have a raised Hb which provokes anxiety and leads to consideration of venesection. Individuals should be evaluated by a respiratory physician for consideration of long-term oxygen therapy or alternative. If the patient is symptomatic of hyperviscosity or has an Hct above 0.56 then venesection should be undertaken to reduce the Hct to 0.50-0.52 [28] . There is also limited evidence to suggest that therapy with drugs such as angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor antagonists should be used in patients who do not tolerate venesection [26] .
Post Renal Transplant
A proportion of patients develop erythrocytosis post renal transplant. The causes of this are not well understood and are likely to be due to multiple factors. The management of this condition includes the avoidance of excessive dehydration and ACE inhibitors or angiotensin II antagonist [29] . If these measures fail, then venesection is considered with a target Hct of less than 0.45 [30] .
Idiopathic Erythrocytosis
This group of patients are those in whom erythrocytosis is present but no cause has been identified. Management guidance is based on the evidence available. Venesection to reduce the Hct to less than a target of 0.50 if it is above 0.54 should be considered. If there is an increased risk of thrombosis that is evidence of ischemia, previous history of thrombosis, peripheral vascular disease, diabetes, or hypertension then a target Hct of 0.45 should be considered if the Hct is above 0.54. Of note in this group, cytoreductive therapy is contraindicated [26] .
Conclusion
An erythrocytosis must be investigated in order to try to determine a possible etiology; however, in many cases, no cause can be discovered. Management options include low dose aspirin and venesection to an achievable target. Specific management guidance is suggested for certain congenital and acquired situations. There is overall a very limited evidence base to guide management and further data collection and studies in some of these rare groups of patients is required.
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